RU2010130161A - Жидкий продукт, содержащий нуклеотиды/нуклеозиды - Google Patents
Жидкий продукт, содержащий нуклеотиды/нуклеозиды Download PDFInfo
- Publication number
- RU2010130161A RU2010130161A RU2010130161/15A RU2010130161A RU2010130161A RU 2010130161 A RU2010130161 A RU 2010130161A RU 2010130161/15 A RU2010130161/15 A RU 2010130161/15A RU 2010130161 A RU2010130161 A RU 2010130161A RU 2010130161 A RU2010130161 A RU 2010130161A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- use according
- specified
- cellulose
- per
- Prior art date
Links
- 239000002773 nucleotide Substances 0.000 title claims abstract 11
- 239000002777 nucleoside Substances 0.000 title claims abstract 4
- 239000012263 liquid product Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 41
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 10
- 239000002562 thickening agent Substances 0.000 claims abstract 9
- 229920002678 cellulose Polymers 0.000 claims abstract 8
- 235000010980 cellulose Nutrition 0.000 claims abstract 8
- 239000007788 liquid Substances 0.000 claims abstract 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract 7
- 239000001913 cellulose Substances 0.000 claims abstract 7
- 239000011574 phosphorus Substances 0.000 claims abstract 7
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 5
- 239000011575 calcium Substances 0.000 claims abstract 5
- 229910052791 calcium Inorganic materials 0.000 claims abstract 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 5
- 229920006318 anionic polymer Polymers 0.000 claims abstract 4
- 150000004676 glycans Chemical class 0.000 claims abstract 4
- 229920001282 polysaccharide Polymers 0.000 claims abstract 4
- 239000005017 polysaccharide Substances 0.000 claims abstract 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract 3
- 229920002148 Gellan gum Polymers 0.000 claims abstract 3
- 239000000216 gellan gum Substances 0.000 claims abstract 3
- 235000010492 gellan gum Nutrition 0.000 claims abstract 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract 3
- 239000000230 xanthan gum Substances 0.000 claims abstract 3
- 229920001285 xanthan gum Polymers 0.000 claims abstract 3
- 235000010493 xanthan gum Nutrition 0.000 claims abstract 3
- 229940082509 xanthan gum Drugs 0.000 claims abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 2
- 206010012289 Dementia Diseases 0.000 claims abstract 2
- 208000018737 Parkinson disease Diseases 0.000 claims abstract 2
- 208000010877 cognitive disease Diseases 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 206010027175 memory impairment Diseases 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 230000009974 thixotropic effect Effects 0.000 claims abstract 2
- 229960001231 choline Drugs 0.000 claims 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
- 235000019743 Choline chloride Nutrition 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229960003178 choline chloride Drugs 0.000 claims 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/262—Cellulose; Derivatives thereof, e.g. ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
- A23L29/272—Gellan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Seasonings (AREA)
Abstract
1. Применение жидкой композиции в изготовлении композиции для предупреждения и/или лечения ухудшения памяти и/или когнитивной дисфункции, болезни Альцгеймера, болезни Паркинсона и/или деменции, причем указанная композиция содержит: ! (i) по меньшей мере, 50 мг нуклеозида и/или нуклеотида на 100 мл; ! (ii) от 0,2 до 10 г белка на 100 мл; и ! (iii) от 0,05 до 3 мас.% загустителя от общей массы композиции, ! в которой указанный загуститель выбран из группы, состоящей из целлюлозы, ксантановой камеди и геллановой камеди, и их смесей. ! 2. Применение по п.1, где указанный загуститель содержит целлюлозу. ! 3. Применение по п.2, где указанная композиция содержит смесь микрокристаллической целлюлозы (МКЦ) и анионного полимерного полисахарида, предпочтительно 0,05-1,0 мас.% указанной смеси от общей массы композиции. ! 4. Применение по п.3, где указанным анионным полимерным полисахаридом является карбоксиметилцеллюлоза (КМЦ). !5. Применение по п.1, где композиция имеет тангенс угла потерь δ между 0,1 и 100, измеренный при любом растяжении в диапазоне 1-100% при 0,1 Гц и 20°С. ! 6. Применение по п.1, причем указанная композиция имеет свойства уменьшения вязкости при сдвиге и/или тиксотропные свойства. ! 7. Применение по п.1, дополнительно включающее от 10 до 150 мг кальция на 100 ккал. ! 8. Применение по п.1, где указанный нуклеотид обеспечивает, по меньшей мере, 30 мас.% от общей массы фосфора в композиции. ! 9. Применение по п.1, где (а) указанный нуклеотид обеспечивает, по меньшей мере, 30 мас.% от общей массы фосфора в композиции, или (б) массовое соотношение белка к кальцию составляет, по меньшей мере, 5, предпочтительно, по меньшей мере, 10, более предпочтительно, по меньшей мере, 25. ! 10.
Claims (21)
1. Применение жидкой композиции в изготовлении композиции для предупреждения и/или лечения ухудшения памяти и/или когнитивной дисфункции, болезни Альцгеймера, болезни Паркинсона и/или деменции, причем указанная композиция содержит:
(i) по меньшей мере, 50 мг нуклеозида и/или нуклеотида на 100 мл;
(ii) от 0,2 до 10 г белка на 100 мл; и
(iii) от 0,05 до 3 мас.% загустителя от общей массы композиции,
в которой указанный загуститель выбран из группы, состоящей из целлюлозы, ксантановой камеди и геллановой камеди, и их смесей.
2. Применение по п.1, где указанный загуститель содержит целлюлозу.
3. Применение по п.2, где указанная композиция содержит смесь микрокристаллической целлюлозы (МКЦ) и анионного полимерного полисахарида, предпочтительно 0,05-1,0 мас.% указанной смеси от общей массы композиции.
4. Применение по п.3, где указанным анионным полимерным полисахаридом является карбоксиметилцеллюлоза (КМЦ).
5. Применение по п.1, где композиция имеет тангенс угла потерь δ между 0,1 и 100, измеренный при любом растяжении в диапазоне 1-100% при 0,1 Гц и 20°С.
6. Применение по п.1, причем указанная композиция имеет свойства уменьшения вязкости при сдвиге и/или тиксотропные свойства.
7. Применение по п.1, дополнительно включающее от 10 до 150 мг кальция на 100 ккал.
8. Применение по п.1, где указанный нуклеотид обеспечивает, по меньшей мере, 30 мас.% от общей массы фосфора в композиции.
9. Применение по п.1, где (а) указанный нуклеотид обеспечивает, по меньшей мере, 30 мас.% от общей массы фосфора в композиции, или (б) массовое соотношение белка к кальцию составляет, по меньшей мере, 5, предпочтительно, по меньшей мере, 10, более предпочтительно, по меньшей мере, 25.
10. Применение по п.1, где указанная композиция имеет содержание сухого вещества между 10 и 40%.
11. Применение по п.1, включающее, по меньшей мере, одну из целлюлоз, выбранных из группы, состоящей из высоковязкой целлюлозы и производных целлюлозы, таких как гидроксиэтилцеллюлоза, гидроксипропилметилцеллюлоза, карбоксиметилцеллюлоза, микрокристаллическая целлюлоза и метилцеллюлоза.
12. Применение по п.1, включающее монофосфат уридина (УМФ) в количестве 0,08-3 г на 100 мл.
13. Применение по п.1, включающее от 50 мг до 3 г холина на 100 мл, причем указанный холин, предпочтительно находится в форме хлорида холина.
14. Жидкая композиция, содержащая:
(i) по меньшей мере, 50 мг нуклеозида и/или нуклеотида на 100 мл;
(ii) от 0,2 до 10 граммов белка на 100 мл; и
(iii) от 0,05 до 3 мас.% загустителя от общей массы композиции,
в которой указанный загуститель выбран из группы, состоящей из целлюлозы, ксантановой камеди и геллановой камеди, и их смесей.
15. Жидкая композиция по п.14, в которой композиция имеет тангенс угла потерь δ между 0,1 и 100, измеренный при любом растяжении в диапазоне 1-100% при 0,1 Гц и 20°С.
16. Жидкая композиция по п.14, содержащая от 10 до 150 мг кальция на 100 ккал.
17. Жидкая композиция по п.14, в которой указанный нуклеотид обеспечивает, по меньшей мере, 30 мас.% от общей массы фосфора в композиции.
18. Питательная композиция, содержащая нуклеотид и загуститель, характеризующаяся тем, что нуклеотид обеспечивает более 30 мас.% от количества фосфора, присутствующего во всей композиции, и композиция содержит от 30 до 80 мг фосфора на 100 ккал.
19. Питательная композиция по п.18, дополнительно содержащая белок и/или минеральное вещество.
20. Жидкая композиция по п.14, которая подвергается ультравысокой температурной обработке (UHT).
21. Жидкая композиция по п.14, содержащая интактный белок.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07123811.7 | 2007-12-20 | ||
EP07123811 | 2007-12-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2010130161A true RU2010130161A (ru) | 2012-01-27 |
RU2446807C2 RU2446807C2 (ru) | 2012-04-10 |
Family
ID=40094223
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010130161/15A RU2446807C2 (ru) | 2007-12-20 | 2008-03-04 | Жидкий продукт, содержащий нуклеотиды/нуклеозиды |
RU2010130160/13A RU2484670C2 (ru) | 2007-12-20 | 2008-12-22 | Приятная на вкус питательная композиция, содержащая нуклеотид и/или нуклеозид и маскирующий вкус агент |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010130160/13A RU2484670C2 (ru) | 2007-12-20 | 2008-12-22 | Приятная на вкус питательная композиция, содержащая нуклеотид и/или нуклеозид и маскирующий вкус агент |
Country Status (12)
Country | Link |
---|---|
US (5) | US8282965B2 (ru) |
EP (3) | EP2222311B1 (ru) |
CN (2) | CN101951923B (ru) |
BR (2) | BRPI0822111B8 (ru) |
DK (1) | DK2244591T3 (ru) |
ES (3) | ES2411726T3 (ru) |
HU (1) | HUE035468T2 (ru) |
MX (2) | MX2010006829A (ru) |
PL (3) | PL2609812T3 (ru) |
PT (1) | PT2244591T (ru) |
RU (2) | RU2446807C2 (ru) |
WO (2) | WO2009082203A1 (ru) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010000224A (es) * | 2007-06-26 | 2010-05-03 | Nutricia Nv | Mejoramiento de la memoria en individuos con mini-examen de estado mental de 24-26. |
WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
WO2009002148A1 (en) | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
WO2009002146A1 (en) * | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
PL2609812T3 (pl) * | 2007-12-20 | 2019-02-28 | N.V. Nutricia | Ciekły produkt zawierający nukleotydy/nukleozydy |
US8916540B2 (en) * | 2008-01-15 | 2014-12-23 | Academia Sinica | Antibiotic compositions and related screening methods |
ES2558609T3 (es) * | 2008-02-01 | 2016-02-05 | Blackberry Limited | Sistema y método para sincronización de temporización de enlace ascendente en combinación con recepción discontinua |
SG10201507554RA (en) | 2010-09-13 | 2015-10-29 | Bev Rx Inc | Aqueous drug delivery system comprising off - flavor masking agent |
EP2621503B1 (en) * | 2010-09-29 | 2017-11-01 | Orkla Foods Sverige AB | Use of a food product comprising viscous fibres which has a beneficial effect on cognitive performance. |
WO2013012313A1 (en) | 2011-07-18 | 2013-01-24 | N.V. Nutricia | Use of a nucleotide for improving the heat stability of an aqueous micellar casein composition |
WO2013066151A1 (en) * | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Improving recognition |
EP2773339A1 (en) * | 2011-10-31 | 2014-09-10 | N.V. Nutricia | Composition for improving neuropsychological test battery score |
WO2013066153A1 (en) * | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Composition for improving neuropsychological test battery score |
WO2013066152A1 (en) * | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Method for improving executive function |
US20150044138A1 (en) * | 2012-03-02 | 2015-02-12 | N.V. Nutricia | Method for improving functional synaptic connectivity |
US20140271998A1 (en) * | 2013-03-15 | 2014-09-18 | Aryeh HECHT | Fortified egg white products |
CA2930919C (en) * | 2013-11-19 | 2021-11-23 | Omniblend Innovation Pty Ltd | Composition comprising protein and fenugreek fibre and uses thereof to control post-prandial blood glucose levels |
WO2015115885A1 (en) * | 2014-01-31 | 2015-08-06 | N.V. Nutricia | Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly |
CN104903857A (zh) * | 2014-04-16 | 2015-09-09 | 华为技术有限公司 | 软件升级方法和终端 |
WO2017069613A1 (en) | 2015-10-23 | 2017-04-27 | N.V. Nutricia | Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients |
WO2017155387A1 (en) * | 2016-03-08 | 2017-09-14 | N.V. Nutricia | Method for supporting memory function and/or cognitive function |
CN115120607A (zh) * | 2022-06-07 | 2022-09-30 | 珍奥集团股份有限公司 | 核苷酸混合物在用于防治阿尔茨海默症制剂中的应用 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3600197A (en) * | 1968-08-27 | 1971-08-17 | Merck & Co Inc | Flavor enhancing compositions for foods and beverages |
AU4595985A (en) | 1984-08-10 | 1986-02-13 | Sentrachem Limited | Cancer treatment |
JP2525624B2 (ja) | 1987-09-21 | 1996-08-21 | 雪印乳業株式会社 | 多価不飽和脂肪酸配合育児用粉乳 |
SU1658975A1 (ru) * | 1988-10-25 | 1991-06-30 | Дальневосточный Технологический Институт Рыбной Промышленности И Хозяйства | Способ интенсификации вкуса пищевых продуктов |
GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
JPH0517372A (ja) | 1991-07-10 | 1993-01-26 | Yoshitomi Pharmaceut Ind Ltd | 不快な味が軽減された生薬配合組成物 |
JPH06237734A (ja) | 1991-11-06 | 1994-08-30 | Sanwa Kagaku Kenkyusho Co Ltd | 機能後退性疾患用食品組成物 |
JPH0717855A (ja) | 1992-09-02 | 1995-01-20 | Maruha Corp | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品 |
US5378488A (en) | 1993-06-10 | 1995-01-03 | Abbott Laboratories | Aseptic processing of infant formula |
US5563177A (en) | 1995-01-30 | 1996-10-08 | American Home Products Corporation | Taste masking guaifenesin containing liquids |
JP3576318B2 (ja) | 1996-06-19 | 2004-10-13 | 明治乳業株式会社 | 核酸関連物質含有栄養組成物 |
JPH10136937A (ja) | 1996-11-08 | 1998-05-26 | Takashi Morita | 脳細胞機能向上、血管細胞強化、身体各細胞機能向上栄養総合食品 |
PT843972E (pt) | 1996-11-20 | 2002-12-31 | Nutricia Nv | Composicao nutritiva que inclui gorduras para o tratamento do sindrome metabolico |
ES2273409T3 (es) | 1997-03-28 | 2007-05-01 | Eisai Co., Ltd. | Medicamento oral que previene el sabor desagradable y similar. |
EP0891719A1 (en) | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Nutritional composition containing methionine |
JP3731983B2 (ja) | 1997-08-27 | 2006-01-05 | 明治製菓株式会社 | 痴呆犬の夜鳴き改善薬 |
US20050203053A1 (en) * | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
US20070004670A1 (en) | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
FR2787799B1 (fr) | 1998-12-23 | 2001-03-09 | Rhodia Chimie Sa | Composition comprenant une ecorce inorganique et un noyau comportant au moins un compose polyhydroxyle |
KR20000046974A (ko) * | 1998-12-31 | 2000-07-25 | 윤재승 | 아세글루타미드 알루미늄의 경구 투여용 제제 조성물ㅇ |
EP1090636A1 (en) | 1999-09-13 | 2001-04-11 | Société des Produits Nestlé S.A. | High lipid diet |
GB9925709D0 (en) | 1999-10-30 | 1999-12-29 | Smithkline Beecham Plc | Composition |
US20020187180A1 (en) | 2000-03-02 | 2002-12-12 | Calton Gary J | Modifying undesirable tastes |
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
DE60138019D1 (de) | 2000-05-01 | 2009-04-30 | Accera Inc | Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung |
US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
CA2594883A1 (en) | 2001-04-30 | 2002-11-07 | Trommsdorff Gmbh & Co. Kg Arzneimittel | Pharmaceutically active uridine esters |
US6942874B2 (en) | 2001-05-25 | 2005-09-13 | Linguagen Corp. | Nucleotide compounds that block the bitter taste of oral compositions |
EP1285590A1 (en) | 2001-08-08 | 2003-02-26 | Société des Produits Nestlé S.A. | Lipid blends |
NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
US20030114415A1 (en) * | 2001-12-14 | 2003-06-19 | Wurtman Richard J. | Compositions and methods for treating and preventing memory impairment using citicoline |
US20040001817A1 (en) | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
PT1721612E (pt) | 2003-10-24 | 2009-09-02 | Nutricia Nv | Oligossacarídeos imunomoduladores |
US7090879B2 (en) | 2004-03-18 | 2006-08-15 | Abbott Laboratories | Nutritional formula containing select carotenoid combinations |
AU2005244816B2 (en) * | 2004-05-13 | 2011-09-29 | Massachusetts Institute Of Technology | Uridine effects on dopamine release |
AU2005285090A1 (en) * | 2004-09-15 | 2006-03-23 | Massachusetts Institute Of Technology | Compositions containing uridine, and methods utilizing same |
EP1656839A1 (en) | 2004-11-11 | 2006-05-17 | N.V. Nutricia | Nutrition containing lipid blend |
US20060252775A1 (en) | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
WO2006127620A2 (en) | 2005-05-23 | 2006-11-30 | Massachusetts Institute Of Technology | Compositions containing pufa and methods of use thereof |
WO2007001883A2 (en) | 2005-06-20 | 2007-01-04 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
JP5697293B2 (ja) | 2005-06-30 | 2015-04-08 | サントリーホールディングス株式会社 | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 |
CA2614473C (en) | 2005-07-08 | 2016-05-03 | Martek Biosciences Corporation | Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions |
WO2007058523A1 (en) | 2005-11-17 | 2007-05-24 | N.V. Nutricia | Composition with docosapentaenoic acid |
US20070140992A1 (en) * | 2005-12-21 | 2007-06-21 | Lynn Schick | Taste masking of essential oils using a hydrocolloid |
EP1800675B1 (en) | 2005-12-23 | 2011-05-18 | N.V. Nutricia | Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia |
MX2010000224A (es) | 2007-06-26 | 2010-05-03 | Nutricia Nv | Mejoramiento de la memoria en individuos con mini-examen de estado mental de 24-26. |
WO2009002148A1 (en) | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
WO2009002146A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
PL2609812T3 (pl) | 2007-12-20 | 2019-02-28 | N.V. Nutricia | Ciekły produkt zawierający nukleotydy/nukleozydy |
JP5397321B2 (ja) | 2009-06-09 | 2014-01-22 | 株式会社デンソー | 駐車支援システム |
-
2008
- 2008-03-04 PL PL13161090T patent/PL2609812T3/pl unknown
- 2008-03-04 WO PCT/NL2008/050124 patent/WO2009082203A1/en active Application Filing
- 2008-03-04 CN CN2008801271501A patent/CN101951923B/zh active Active
- 2008-03-04 RU RU2010130161/15A patent/RU2446807C2/ru active
- 2008-03-04 ES ES08723875T patent/ES2411726T3/es active Active
- 2008-03-04 BR BRPI0822111A patent/BRPI0822111B8/pt active IP Right Grant
- 2008-03-04 MX MX2010006829A patent/MX2010006829A/es active IP Right Grant
- 2008-03-04 US US12/809,418 patent/US8282965B2/en active Active
- 2008-03-04 ES ES13161090T patent/ES2697149T3/es active Active
- 2008-03-04 EP EP08723875A patent/EP2222311B1/en active Active
- 2008-03-04 EP EP13161090.9A patent/EP2609812B1/en not_active Revoked
- 2008-03-04 PL PL08723875T patent/PL2222311T3/pl unknown
- 2008-12-22 US US12/809,431 patent/US8604000B2/en active Active
- 2008-12-22 DK DK08864664.1T patent/DK2244591T3/en active
- 2008-12-22 ES ES08864664.1T patent/ES2645864T3/es active Active
- 2008-12-22 PL PL08864664T patent/PL2244591T3/pl unknown
- 2008-12-22 BR BRPI0821636-3A2A patent/BRPI0821636A2/pt not_active Application Discontinuation
- 2008-12-22 WO PCT/NL2008/050843 patent/WO2009082227A1/en active Application Filing
- 2008-12-22 HU HUE08864664A patent/HUE035468T2/en unknown
- 2008-12-22 RU RU2010130160/13A patent/RU2484670C2/ru not_active IP Right Cessation
- 2008-12-22 EP EP08864664.1A patent/EP2244591B1/en not_active Revoked
- 2008-12-22 MX MX2010006830A patent/MX2010006830A/es not_active Application Discontinuation
- 2008-12-22 PT PT88646641T patent/PT2244591T/pt unknown
- 2008-12-22 CN CN200880127153.5A patent/CN101951790B/zh active Active
-
2012
- 2012-09-14 US US13/620,442 patent/US20130012469A1/en not_active Abandoned
-
2013
- 2013-12-03 US US14/095,676 patent/US9132196B2/en active Active
-
2015
- 2015-08-31 US US14/840,655 patent/US9687555B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010130161A (ru) | Жидкий продукт, содержащий нуклеотиды/нуклеозиды | |
MX2009006882A (es) | Derivados de indol como agonistas del receptor s1p1. | |
BRPI0607869A2 (pt) | hidroxietilcelulose em bloco, derivados da mesma, processos de fabricação e usos da mesma | |
BRPI0615307A2 (pt) | agonistas de adrenorreceptor alfa2c | |
TW200609235A (en) | Tetraazabenzo[e]azulene derivatives and analogs thereof | |
BRPI0608250A2 (pt) | hidroxietilcelulose de baixa substituição solúvel em água, derivados da mesma, processo de produção e usos da mesma | |
MA33044B1 (fr) | Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient | |
CY1111444T1 (el) | Μεθοδοι για την παραγωγη τελικων προϊοντων απο υποστρωματα ανθρακα | |
WO2008152099A3 (en) | Aryl/hetarylamides as modulators of the ep2 receptor | |
MX2007013065A (es) | Derivados de dihidrobenzofurano y usos de los mismos. | |
HUP0001037A2 (hu) | Eljárás kedvező hatású adalék leválásának fokozására mosdószappanból, valamint ilyen módon előállított mosdószappan | |
PH12013502369A1 (en) | Diazacarbazoles and methods of use | |
BRPI0419182A (pt) | uso de uma composição, composição espessante de produtos nutricionais, produto nutricional espessado, e, método para preparar um produto nutricional espessado | |
MX2007003107A (es) | Polisacaridos con guanidina, su uso como absorbentes y proceso para producir los mismos. | |
WO2008152093A3 (en) | Diaminopyrimidines as modulators of the ep2 receptor | |
NO20080943L (no) | Fremstilling av krystallinsk kortkjedet amylose | |
MX2009013676A (es) | Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa. | |
MX2010003488A (es) | Composiciones de oftalmologia basadas en polisacarido y acido hialuronico de semillas de tamarindo. | |
EA200801980A1 (ru) | Шихта для получения металлургического кокса (варианты) | |
TR201909129T4 (tr) | Korteksolon-17-alfa-propiyonat içeren farmasötik bileşimler. | |
ZA200810031B (en) | 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use for the manufacture of medicaments | |
Keeratiburana et al. | Pre-treatment of granular rice starch to enhance branching enzyme catalysis | |
MX2009008777A (es) | Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos. | |
MX2009005679A (es) | Fluoresceina sustancialmente pura. | |
NO20091832L (no) | Indoler som virker via reseptorantagonister |